Please read about our work here.
Ollila lab studies interplay between stromal and epithelial cells in gastrointestinal health and disease. We are particularly interested in the role of subepithelial fibroblasts and gastrointestinal nerves in regulating intestinal stem cells and gastrointestinal tumorigenesis.
- Lemmetyinen TT, Viitala EW, Wartiovaara L, Kaprio T, Hagström J, Haglund C, Katajisto P, Wang TC, Domènech-Moreno E, Ollila S. Fibroblast-derived EGF ligand Neuregulin-1 induces fetal-like reprogramming of the intestinal epithelium without supporting tumorigenic growth. Dis Model Mech. 2023 Mar 13:dmm.049692. doi: 10.1242/dmm.049692. PMID: 36912192.
- Domènech-Moreno E, Brandt A, Lemmetyinen TT, Wartiovaara L, Mäkelä TP, Ollila S. Tellu - an object-detector algorithm for automatic classification of intestinal organoids. Dis Model Mech. 2023 Mar 1;16(3):dmm049756. doi: 10.1242/dmm.049756. Epub 2023 Mar 13. PMID: 36804687.
- Mätlik K, Olfat S, Cowlishaw MC, Moreno ED, Ollila S, Andressoo JO. In vivo modulation of endogenous gene expression via CRISPR/Cas9-mediated 3'UTR editing. Heliyon. 2023 Feb 24;9(3):e13844. doi: 10.1016/j.heliyon.2023.e13844. PMID: 36923835; PMCID: PMC10009458.
- Ollila S, Domènech-Moreno E, Laajanen K, Wong IP, Tripathi S, Pentinmikko N, Gao Y, Yan Y, Niemelä EH, Wang TC, Viollet B, Leone G, Katajisto P, Vaahtomeri K, Mäkelä TP. Stromal Lkb1 deficiency leads to gastrointestinal tumorigenesis involving the IL-11-JAK/STAT3 pathway. J Clin Invest. 2018 Jan 2;128(1):402-414. doi: 10.1172/JCI93597. Epub 2017 Dec 4. PubMed PMID: 29202476; PubMed Central PMCID: PMC5749537.
- Dermadi D, Valo S, Ollila S, Soliymani R, Sipari N, Pussila M, Sarantaus L, Linden J, Baumann M, Nyström M. Western Diet Deregulates Bile Acid Homeostasis, Cell Proliferation, and Tumorigenesis in Colon. Cancer Res. 2017 Jun 15;77(12):3352-3363. doi: 10.1158/0008-5472.CAN-16-2860. Epub 2017 Apr 17. PubMed PMID: 28416481.
- Yan Y, Ollila S, Wong IPL, Vallenius T, Palvimo JJ, Vaahtomeri K, Mäkelä TP. SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling. Nat Commun. 2015 Nov 30;6:8979. doi: 10.1038/ncomms9979. PubMed PMID: 26616021; PubMed Central PMCID: PMC4674823.
- Pussila M, Sarantaus L, Dermadi Bebek D, Valo S, Reyhani N, Ollila S, Päivärinta E, Peltomäki P, Mutanen M, Nyström M. Cancer-predicting gene expression changes in colonic mucosa of Western diet fed Mlh1+/- mice. PLoS One. 2013;8(10):e76865. doi: 10.1371/journal.pone.0076865. eCollection 2013. PubMed PMID: 24204690; PubMed Central PMCID: PMC3815089.
- Ollila S, Mäkelä TP. The tumor suppressor kinase LKB1: lessons from mouse models. J Mol Cell Biol. 2011 Dec;3(6):330-40. doi: 10.1093/jmcb/mjr016. Epub 2011 Sep 15. Review. PubMed PMID: 21926085.
- Kantelinen J, Hansen TV, Kansikas M, Krogh LN, Korhonen MK, Ollila S, Nyström M, Gerdes AM, Kariola R. A putative Lynch syndrome family carrying MSH2 and MSH6 variants of uncertain significance-functional analysis reveals the pathogenic one. Fam Cancer. 2011 Sep;10(3):515-20. doi: 10.1007/s10689-011-9436-z. PubMed PMID: 21431882.
- Kantelinen J, Kansikas M, Korhonen MK, Ollila S, Heinimann K, Kariola R, Nyström M. MutSbeta exceeds MutSalpha in dinucleotide loop repair. Br J Cancer. 2010 Mar 16;102(6):1068-73. doi: 10.1038/sj.bjc.6605531. Epub 2010 Feb 16. PubMed PMID: 20160730; PubMed Central PMCID: PMC2844022.
- Gargiulo S, Torrini M, Ollila S, Nasti S, Pastorino L, Cusano R, Bonelli L, Battistuzzi L, Mastracci L, Bruno W, Savarino V, Sciallero S, Borgonovo G, Nyström M, Bianchi-Scarrà G, Mareni C, Ghiorzo P. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Fam Cancer. 2009;8(4):547-53. doi: 10.1007/s10689-009-9285-1. PubMed PMID: 19728162.
- Ollila S, Dermadi Bebek D, Jiricny J, Nyström M. Mechanisms of pathogenicity in human MSH2 missense mutants. Hum Mutat. 2008 Nov;29(11):1355-63. doi: 10.1002/humu.20893. PubMed PMID: 18951462.
- Ollila S, Dermadi Bebek D, Greenblatt M, Nyström M. Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification. Int J Cancer. 2008 Aug 1;123(3):720-4. doi: 10.1002/ijc.23573. PubMed PMID: 18470917.
- Chan PA, Duraisamy S, Miller PJ, Newell JA, McBride C, Bond JP, Raevaara T, Ollila S, Nyström M, Grimm AJ, Christodoulou J, Oetting WS, Greenblatt MS. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat. 2007 Jul;28(7):683-93. doi: 10.1002/humu.20492. PubMed PMID: 17370310.
- Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F, Kohonen-Corish M, Gerdes AM, Peltomäki P, Mangold E, de la Chapelle A, Greenblatt M, Nyström M. Pathogenicity of MSH2 missense mutations is typically associated with impaired repair capability of the mutated protein. Gastroenterology. 2006 Nov;131(5):1408-17. doi: 10.1053/j.gastro.2006.08.044. Epub 2006 Aug 22. PubMed PMID: 17101317.
- Zhang J, Lindroos A, Ollila S, Russell A, Marra G, Mueller H, Peltomaki P, Plasilova M, Heinimann K. Gene conversion is a frequent mechanism of inactivation of the wild-type allele in cancers from MLH1/MSH2 deletion carriers. Cancer Res. 2006 Jan 15;66(2):659-64. doi: 10.1158/0008-5472.CAN-05-4043. PubMed PMID: 16423994.
- Ollila S, Fitzpatrick R, Sarantaus L, Kariola R, Ambus I, Velsher L, Hsieh E, Andersen MK, Raevaara TE, Gerdes AM, Mangold E, Peltomäki P, Lynch HT, Nyström M. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC. Int J Oncol. 2006 Jan;28(1):149-53. PubMed PMID: 16327991